For in vitro analysis of the antitumor reactivities of the developed CAR-T products, meso-I- or meso-III-redirected CAR-Ts were co-cultivated with the human gastric carcinoma cell line HGC-27 or human ovarian cancer cell line SKOV3, and it was demonstrated that meso-III-redirected CAR-Ts exhibited more pronounced tumoricidal effects against the target cells, as they also secreted higher levels of IL-2, INF-γ, and TNF-α, and demonstrated a higher expression rate of CD107α in comparison with those of meso-I-redirected CAR-Ts (144). This evidence concerns the gene IL2 and ovarian carcinoma.